Brokerages Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Price Target at $11.40

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have been assigned an average recommendation of “Buy” from the seven brokerages that are presently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $11.40.

Several analysts recently issued reports on RVPH shares. D. Boral Capital reiterated a “buy” rating and set a $15.00 price objective on shares of Reviva Pharmaceuticals in a report on Tuesday, January 21st. Roth Mkm initiated coverage on Reviva Pharmaceuticals in a report on Friday, January 10th. They set a “buy” rating and a $7.00 price target for the company. Maxim Group raised Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research note on Friday, January 10th. HC Wainwright cut their price objective on shares of Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. Finally, Roth Capital raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 10th.

Reviva Pharmaceuticals Price Performance

NASDAQ RVPH opened at $0.95 on Thursday. The firm has a market capitalization of $31.90 million, a price-to-earnings ratio of -0.86 and a beta of -0.09. The company has a 50 day simple moving average of $1.51 and a 200-day simple moving average of $1.47. Reviva Pharmaceuticals has a 52-week low of $0.60 and a 52-week high of $4.28.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its earnings results on Monday, March 31st. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. On average, analysts predict that Reviva Pharmaceuticals will post -0.97 EPS for the current year.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in RVPH. Raymond James Financial Inc. acquired a new position in Reviva Pharmaceuticals during the 4th quarter worth $25,000. Cornerstone Select Advisors LLC bought a new position in shares of Reviva Pharmaceuticals in the fourth quarter worth about $32,000. Drive Wealth Management LLC acquired a new position in shares of Reviva Pharmaceuticals during the 4th quarter worth about $36,000. XTX Topco Ltd bought a new stake in Reviva Pharmaceuticals during the 4th quarter valued at approximately $45,000. Finally, Tower Research Capital LLC TRC boosted its stake in Reviva Pharmaceuticals by 848.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 26,775 shares of the company’s stock valued at $48,000 after purchasing an additional 23,953 shares during the period. 63.18% of the stock is currently owned by institutional investors and hedge funds.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.